Patents Examined by Ernst V. Arnold
-
Patent number: 11564938Abstract: Provided herein are methods for maintaining physiological levels of nitrite in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium nitrite to a subject undergoing hemodialysis.Type: GrantFiled: November 23, 2020Date of Patent: January 31, 2023Assignee: Hope Medical Enterprises, Inc.Inventor: Craig Sherman
-
Patent number: 11564790Abstract: A method includes forming a scaffold and seeding the scaffold with live cells; growing the cells in the scaffold; and 3D printing the cells into a living subject, where the cells continue to live in the living subject.Type: GrantFiled: October 14, 2019Date of Patent: January 31, 2023Inventor: Mariela Aguilar
-
Patent number: 11565094Abstract: Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.Type: GrantFiled: October 17, 2018Date of Patent: January 31, 2023Assignee: THE METHODIST HOSPITAL SYSTEMInventors: Marco Farina, Andrea Ballerini, Daniel W. Fraga, Usha Ramachandran Thekkedath, Omaima M. Sabek, Ahmed Osama Gaber, Alessandro Grattoni
-
Patent number: 11564885Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.Type: GrantFiled: February 22, 2022Date of Patent: January 31, 2023Assignee: OTSUKA PHARMACEUTICAL CO, LTD.Inventors: Syed Asfar Mateen, Praveen Kumar Mididoddi, Shailly Mehrotra, Susan Elizabeth Shoaf, Salin Gupta, Kai Suzuki, Masahiro Hasegawa
-
Patent number: 11559492Abstract: The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.Type: GrantFiled: March 2, 2020Date of Patent: January 24, 2023Assignee: Applied Materials, Inc.Inventors: Pekka Hoppu, Tommi Kaariainen, Marja-Leena Kaariainen, Aimo Turunen
-
Patent number: 11547116Abstract: Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.Type: GrantFiled: December 13, 2013Date of Patent: January 10, 2023Inventors: William Wingfield, Guerry L Grune, Richard L Mason
-
Patent number: 11541011Abstract: A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.Type: GrantFiled: November 7, 2018Date of Patent: January 3, 2023Assignee: MATERIAS S.r.l.Inventors: Pasquale Del Gaudio, Rita Patrizia Aquino, Paola Russo, Gianluigi De Falco, Luigi Nicolais
-
Patent number: 11529310Abstract: The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein the dosage form and the bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.Type: GrantFiled: December 7, 2021Date of Patent: December 20, 2022Assignee: RUMINANT BIOTECH CORP LIMITEDInventors: Mark Christopher Lay, Hayden Peter Thomas, Neil Richard Gladden, David Leslie Hayman, Geoffrey Earle Corbett, Prabhat Bhusal
-
Patent number: 11529329Abstract: A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.Type: GrantFiled: May 27, 2016Date of Patent: December 20, 2022Assignee: NORDICCAN A/SInventor: Søren Christian Schou
-
Patent number: 11517522Abstract: The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: GrantFiled: January 13, 2021Date of Patent: December 6, 2022Assignee: SOMERSET THERAPEUTICS LLCInventors: Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian
-
Patent number: 11517646Abstract: A scaffold for tissue repair or wound dressing comprising: a material layer; a polymer fibre layer; and an adhesive component between the material layer and the polymer fibre layer, wherein the adhesive component comprises material having a lower melting temperature (Tm) than the material layer and the polymer fibre layer.Type: GrantFiled: November 19, 2019Date of Patent: December 6, 2022Assignee: Oxford University Innovation LimitedInventors: Osnat Hakimi, Pierre-Alexis Mouthuy, Nasim Zargar Baboldashti, Andrew Carr
-
Patent number: 11510963Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.Type: GrantFiled: August 2, 2022Date of Patent: November 29, 2022Assignee: Amryt Endo, Inc.Inventors: Roni Mamluk, Sam Teichman
-
Patent number: 11510893Abstract: Stable methocarbamol ready to use compositions for parenteral administration including parenteral infusion are provided. In certain embodiments, the compositions are sterile, isotonic, and particulate-matter-free. Further, the compositions reduce or avoid allergic reactions to latex, reduce or avoid extravasation, and permit administration of methocarbamol to subjects having renal pathology. Methods of manufacture and methods of administration are also provided.Type: GrantFiled: January 19, 2022Date of Patent: November 29, 2022Assignee: Exela Sterile Medicines LLCInventors: Phanesh B. Koneru, John Maloney
-
Patent number: 11504340Abstract: The invention provides methods of making microparticle and nanoparticle ocular implants from a compositions comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent.Type: GrantFiled: May 10, 2018Date of Patent: November 22, 2022Assignee: THE QUEEN'S UNIVERSITY OF BELFASTInventors: Raghu Raj Singh Thakur, David Jones, Rahul Sonawane
-
Patent number: 11504447Abstract: The present invention relates to methods for producing biphasic calcium phosphate materials using chemical processing methods including exposure to peroxides. The resulting materials exhibit an osteoinductive needle-like surface morphology and are useful as artificial bone grafts.Type: GrantFiled: August 27, 2020Date of Patent: November 22, 2022Assignee: SECADA MEDICAL LLCInventors: Sahil Jalota, Russell Cook
-
Patent number: 11497764Abstract: Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.Type: GrantFiled: November 30, 2020Date of Patent: November 15, 2022Assignee: Purdue Research FoundationInventors: You-Yeon Won, Hyun Chang Kim
-
Patent number: 11497831Abstract: Methods of bioprinting a bio-ink construct on an internal tissue defect or a chondral defect during a minimally invasive surgery on an individual in need thereof are provided, comprising: visualizing the defect; positioning a bioprinter comprising a printhead within proximity of or in contact with the defect; and ejecting a bio-ink from the printhead onto the defect to form a bio-ink layer, thereby generating a bio-ink construct. Further provided are systems for bioprinting a bio-ink construct on an internal tissue defect during a minimally invasive surgery on an individual in need thereof, comprising a control system, an endoscope, and a bioprinter comprising a printhead.Type: GrantFiled: May 25, 2017Date of Patent: November 15, 2022Assignee: SCRIPPS HEALTHInventors: Darryl D. D'Lima, Clifford W. Colwell, Jr.
-
Patent number: 11484504Abstract: The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.Type: GrantFiled: December 29, 2017Date of Patent: November 1, 2022Assignees: Laxxon Medical AG, Exentis Knowledge GmbHInventors: Achim Schneeberger, Klaus Kühne, Helmut Kerschbaumer, Srdan Vasic
-
Patent number: 11478447Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.Type: GrantFiled: January 13, 2022Date of Patent: October 25, 2022Assignee: CANNA CHEMISTRIES LLCInventors: Emily Rigsbee, David T. Jonaitis, Nathan Schultheiss, Lloyd Steven Miller
-
Patent number: 11458159Abstract: The present invention refers to an oxygen carrier, preferably hemoglobin or myoglobin, for use in the treatment of an unpleasant feeling of a body surface due to a disease or a disorder.Type: GrantFiled: June 20, 2018Date of Patent: October 4, 2022Assignee: MÖLNLYCKE HEALTH CARE ABInventor: Michael Sander